ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,261.80
0.50%
S&P ASX All Technology
3,859.50
0.90%
Brent Oil
73.44
0.00%
US Dollar vs AUD
1.61005
0.00%
Bitcoin
94,449.73
0.31%
Pepperstone
Advertisement
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Dare Bioscience Inc (DARE) Share Price

Dare Bioscience Inc

Dare Bioscience Inc (DARE)

NASDAQ
3.27
-0.03
(-0.91%)
Closed 28 December 8:00AM
Delayed by 15 minutes
3.27
0.00
(0.00%)
After Hours: 8:56AM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
3.27
Bid
3.18
Offer
3.36
Volume
14,780
3.24 Day's Range 3.315
2.6703 52 Week Range 7.56
Market Cap
28.45M
Previous Close
3.30
Open
3.26
Last Trade
9
@
3.1801
Last Trade Time
Financial Volume
US$ 48,286
VWAP
3.267
Average Volume (3m)
52,403
Shares Outstanding
8,700,389
Dividend Yield
-
PE Ratio
-0.94
Earnings Per Share (EPS)
-3.47
Revenue
2.81M
Net Profit
-30.16M

About Dare Bioscience Inc

Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve... Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.darebioscience.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Dare Bioscience Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker DARE. The last closing price for Dare Bioscience was US$3.30. Over the last year, Dare Bioscience shares have traded in a share price range of US$ 2.6703 to US$ 7.56.

Dare Bioscience currently has 8,700,389 shares in issue. The market capitalisation of Dare Bioscience is US$28.71 million. Dare Bioscience has a price to earnings ratio (PE ratio) of -0.94.

Ask ADVFN Intelligence (AI)

DARE Latest News

More News

Form 8-K - Current report

17 December 2024
Edgar (US Regulatory)

Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)

FSAD is clinically analogous to erectile dysfunction in men.To date, there are no FDA-approved pharmacological treatments for FSAD; Daré’s Sildenafil Cream has the potential to receive the first...

17 December 2024
GlobeNewswire Inc.

Daré Bioscience Announces Publication in Sexual Medicine of Positive Findings from Demographic, Behavioral and Medication Use Subgroup Analyses in the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%

SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced that additional data from the...

11 December 2024
GlobeNewswire Inc.

Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Daré Bioscience’s DARE-LARC1 Platform Technology has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases Strategic Process Underway to Explore Partnering...

05 December 2024
GlobeNewswire Inc.

Form EFFECT - Notice of Effectiveness

27 November 2024
Edgar (US Regulatory)

Form 424B3 - Prospectus [Rule 424(b)(3)]

27 November 2024
Edgar (US Regulatory)

Form D - Notice of Exempt Offering of Securities

23 November 2024
Edgar (US Regulatory)

Form S-1 - General form for registration of securities under the Securities Act of 1933

16 November 2024
Edgar (US Regulatory)

Form 8-K - Current report

15 November 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

15 November 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.3612.37113402062.913.3452.6703579143.01720282CS
4-0.04-1.20845921453.313.752.6703633393.23273064CS
120.092.830188679253.184.62.6703524033.50436078CS
26-1.3704-29.5319369024.64045.0282.6703729823.82808384CS
52-0.93-22.14285714294.27.562.67033096524.56739203CS
156-21.93-87.023809523825.225.322.670357195813.53772895CS
260-6.45-66.35802469149.7246.22.6703148300119.75174658CS

DARE - Frequently Asked Questions (FAQ)

What is the current Dare Bioscience share price?
The current share price of Dare Bioscience is US$ 3.27
How many Dare Bioscience shares are in issue?
Dare Bioscience has 8,700,389 shares in issue
What is the market cap of Dare Bioscience?
The market capitalisation of Dare Bioscience is USD 28.71M
What is the 1 year trading range for Dare Bioscience share price?
Dare Bioscience has traded in the range of US$ 2.6703 to US$ 7.56 during the past year
What is the PE ratio of Dare Bioscience?
The price to earnings ratio of Dare Bioscience is -0.94
What is the cash to sales ratio of Dare Bioscience?
The cash to sales ratio of Dare Bioscience is 10.1
What is the reporting currency for Dare Bioscience?
Dare Bioscience reports financial results in USD
What is the latest annual turnover for Dare Bioscience?
The latest annual turnover of Dare Bioscience is USD 2.81M
What is the latest annual profit for Dare Bioscience?
The latest annual profit of Dare Bioscience is USD -30.16M
What is the registered address of Dare Bioscience?
The registered address for Dare Bioscience is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Dare Bioscience website address?
The website address for Dare Bioscience is www.darebioscience.com
Which industry sector does Dare Bioscience operate in?
Dare Bioscience operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
INTZIntrusion Inc
US$ 2.167
(381.56%)
187.57M
AILEiLearningEngines Inc
US$ 0.5932
(267.31%)
557.72M
HUBCWHub Cyber Security Ltd
US$ 0.035
(250.00%)
2.65M
GTIGraphjet Technology
US$ 0.967551
(185.83%)
398.75M
LITMSnow Lake Resources Ltd
US$ 1.61
(82.95%)
129.92M
NEUPNeuphoria Therapeutics Inc
US$ 4.11
(-92.30%)
936.47k
VIRXViracta Therapeutics Inc
US$ 0.16
(-32.49%)
9.31M
PRFXPainReform Ltd
US$ 3.48
(-28.98%)
926.19k
AIREreAlpha Tech Corporation
US$ 2.56
(-28.49%)
8.26M
AVGRAvinger Inc
US$ 0.9721
(-24.05%)
2.11M
AILEiLearningEngines Inc
US$ 0.5932
(267.31%)
563.26M
GTIGraphjet Technology
US$ 0.967551
(185.83%)
398.94M
RGTIRigetti Computing Inc
US$ 17.08
(10.62%)
305.78M
XTIAXTI Aerospace Inc
US$ 0.03935
(-1.63%)
267.99M
QSIQuantum Si Inc
US$ 3.585
(66.74%)
256.01M

DARE Discussion

View Posts
Monksdream Monksdream 4 months ago
DARE under $4
👍️0
powerbattles powerbattles 7 months ago
$DARE took the starter! Secure $22 million in the non-dilutive & phase 2 and phase 3 coming $$$
👍️0
harry crumb harry crumb 8 months ago
Wouldn’t touch this turd with monopoly money until after the r/s, an after the shorting!
👍️0
Awl416 Awl416 8 months ago
Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts
👍️0
willlbone willlbone 8 months ago
Vote on R/S.
👍️0
glenn1919 glenn1919 10 months ago
DARE.................................................https://stockcharts.com/h-sc/ui?s=DARE&p=W&b=5&g=0&id=p86431144783
👍️0
starkd748 starkd748 1 year ago
It's dead lol
👍️0
Monksdream Monksdream 1 year ago
DARE new 52 week low
👍️0
Monksdream Monksdream 1 year ago
DARE new 52 week low
👍️0
Monksdream Monksdream 1 year ago
DARE new 52 week low
👍️0
Monksdream Monksdream 1 year ago
DARE newb52 week low
👍️0
harry crumb harry crumb 2 years ago
Might be a runner in due time
👍️0
nonsequetor nonsequetor 2 years ago
The DARE train has not even left the station... gathering up steam...
👍️0
harry crumb harry crumb 2 years ago
1.00 average, 100k
👍️0
nonsequetor nonsequetor 2 years ago
I hope everyone loaded up Monday...
👍️0
nonsequetor nonsequetor 2 years ago
Monday, Jan 23, is the day...
👍️0
harry crumb harry crumb 2 years ago
Yep agree
👍️0
nonsequetor nonsequetor 2 years ago
If Ovaprene is approved by the FDA, it could be the first monthly non-hormonal contraceptive product for women and a first-in-category option for women seeking a hormone-free, self-administered and monthly birth control method.

https://www.biospace.com/article/releases/dare-bioscience-announces-ide-approval-for-a-single-arm-open-label-pivotal-contraceptive-efficacy-study-of-ovaprene-an-investigational-hormone-free-monthly-intravaginal-contraceptive/
👍️0
nonsequetor nonsequetor 2 years ago
DARE starts revenue soon with its first approved drug, Xaciato and its licensing partner OGN. Q1 or Q2. Milestone payments and double digit royalties.

Additionally, they have up to three products entering Ph3 trials this year: Ovaprene, Sildenafil and HRT-1. Ovaprene for sure is entering Ph3 this summer with NIH and licensing partner $BAYRY.

By 2024, they could have FDA-approved products and $4-$5B market share and exclusivity.
👍️0
nonsequetor nonsequetor 2 years ago
DARE Since Post:
$0.3266
(38.27%)
Then:$0.8534
Now:$1.18

Nice chunk of change so far...
👍️0
harry crumb harry crumb 2 years ago
Mayb, mayb not
👍️0
nonsequetor nonsequetor 2 years ago
Since my call
Jan 03, 2023 9:29 AM

$DARE It has begun...

DARE Since Post:
$0.2566
(30.07%)
Then:$0.8534
Now:$1.11

UM...AH... looks like a winner already...
and it has not even started!

BUT...

I really don't care what negativity others post. I have done my DD, bought low, and will ride the wave to prosperity.

DARE is the real thing, with one of a kind, first in class products, that will turn many heads and make some (who do their own DD) wealthy.

Good fortune to all (except shorts, who bet wrong on this leg up).
👍️0
harry crumb harry crumb 2 years ago
Could be but highly unlikely this becomes a winner
👍️0
nonsequetor nonsequetor 2 years ago
Just a little bit of DD will prove you wrong.
👍️0
harry crumb harry crumb 2 years ago
Dont count on it, this team is not an has not proven anything yet. Could use new management for a change, the stock does note promote a very good company
👍️0
nonsequetor nonsequetor 2 years ago
Hop aboard, this is just the beginning!
👍️0
nonsequetor nonsequetor 2 years ago
DARE up over 30% already this year.
👍️0
nonsequetor nonsequetor 2 years ago
Up 20% in 2 days
👍️0
nonsequetor nonsequetor 2 years ago
UP 10% since yesterday morning.
👍️0
harry crumb harry crumb 2 years ago
This pos needs to be shutdown, what a scam
👍️0
harry crumb harry crumb 2 years ago
Some more news on dare
👍️0
nonsequetor nonsequetor 2 years ago
Daré Bioscience Announces Subject Screening for Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Complete

https://finance.yahoo.com/news/dar-bioscience-announces-subject-screening-120000980.html
👍️0
harry crumb harry crumb 2 years ago
Some news an this turd is stagnant, very boring company here
👍️0
harry crumb harry crumb 2 years ago
Looks like this pos is going to its 3 yr low of .75 area. What junk!
👍️0
nonsequetor nonsequetor 2 years ago
Q4 will be interesting
👍️0
nonsequetor nonsequetor 2 years ago
WOW!! Nice EOD catapult!!
👍️0
nonsequetor nonsequetor 2 years ago
Another week... another wait...

ZZZZZZZZZZZZZZZZZZZZZZ
👍️0
MattSav MattSav 2 years ago
Good looking week... Hope everyone is enjoying this move upwards... I know we are waiting on 4th quarter for real numbers but wondering if the sentiment here is good enough to through another 10k on shares lol
👍️0
nonsequetor nonsequetor 2 years ago
YES!
👍️0
MattSav MattSav 2 years ago
So should we be excited that they are doing Financials on a Tuesday?
👍️0
MattSav MattSav 2 years ago
So is the corporate presentation today or what I can't open the damn thing
👍️0
nonsequetor nonsequetor 2 years ago
https://www.sec.gov/Archives/edgar/data/0001401914/000149315222019342/ex3-1.htm
👍️0
MattSav MattSav 2 years ago
Anyone find out how the vote went?
👍️0
kruy kruy 2 years ago
You do realize that all the upfront payments and tiered royalties have to be split with the labs that actually invented and produce these products. DARE is only the middleman. These details are all spelled out in the last SEC annual filing.
The best thing that could happen for us shareholders is that some big company that needs a pipeline will buy out this company and its entire complicated business model. Give me $5 a share and I'm happy. Reality wise, I think we could only get $3-$4 because they would need to come to agreements with all the labs that actually engineered all of the products. Either way, I'd be happy with any buyout because the business model as is could take a long time for DARE to break even or show a profit after splitting royalties with all parties involved.
👍️0
nonsequetor nonsequetor 2 years ago
$$$$ Coming in from the Gates!
https://ih.advfn.com/stock-market/NASDAQ/dare-bioscience-DARE/stock-news/88547783/current-report-filing-8-k
👍️0
nonsequetor nonsequetor 3 years ago
This DARE stock will drive a sane man crazy!
👍️0
harry crumb harry crumb 3 years ago
Employee stock incentive plan goes into effect with dare Bod approval. Always good news to have a employee purchase plan for company stock
👍️0
MattSav MattSav 3 years ago
So im new to this stock... What are the opinions of the stock not getting its approval to increase shares?
👍️0
nonsequetor nonsequetor 3 years ago
Just a few more days...
👍️0
nonsequetor nonsequetor 3 years ago
CLINICAL TRIALS RESULTS JUST POSTED
https://www.clinicaltrials.gov/ct2/show/results/NCT03598088?view=results
👍️0

Your Recent History

NASDAQ
DARE
Dare Bioscience
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads